drugset / Trial / NCT02664649

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

NCT02664649

RandomizedParallel-groupOpen-labelTreatment

Summary

ATLANTIS is a multicenter, phase IIIb, prospective, open-label, randomized trial. The objective of this study is to demonstrate superiority of a strategy of anticoagulation with apixaban (Anti-Xa Group) as compared to the current standard of care in patients who have undergone a successful TAVI procedure. The randomization is stratified according to the presence or not of a mandatory indication for anticoagulation for a reason other than the TAVI procedure (e.g. atrial fibrillation or DVT/PE).

Timeline

Start
2016-08-26
Primary completion
2020-10-15
Completion
2020-10-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral
Subject Apixaban Small molecule 5 mg Oral

Indications